Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere

Beitrag in einer Fachzeitschrift


Details zur Publikation

Autorinnen und Autoren: Woodward DF, Wang JW, Stamer WD, Lütjen-Drecoll E, Krauss AHP, Toris CB
Zeitschrift: Journal of Ocular Pharmacology and Therapeutics
Jahr der Veröffentlichung: 2019
ISSN: 1080-7683


Abstract

For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.


FAU-Autorinnen und Autoren / FAU-Herausgeberinnen und Herausgeber

Lütjen-Drecoll, Elke Prof. Dr.
Lehrstuhl für Funktionelle und Klinische Anatomie


Einrichtungen weiterer Autorinnen und Autoren

Duke University
Imperial College London / The Imperial College of Science, Technology and Medicine
University of Nebraska Medical Center


Zitierweisen

APA:
Woodward, D.F., Wang, J.W., Stamer, W.D., Lütjen-Drecoll, E., Krauss, A.H.-P., & Toris, C.B. (2019). Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere. Journal of Ocular Pharmacology and Therapeutics. https://dx.doi.org/10.1089/jop.2019.0041

MLA:
Woodward, David F., et al. "Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere." Journal of Ocular Pharmacology and Therapeutics (2019).

BibTeX: 

Zuletzt aktualisiert 2019-13-08 um 11:23